Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Aurigene, Curis deal

    Aurigene Discovery Technologies Ltd., Bangalore, India Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Business: Cancer Under a two-year deal, Aurigene granted Curis options to license exclusive, worldwide rights to small …

    Published on 1/26/2015
  • Cardiome, Aspen deal

    Cardiome Pharma Corp. (TSX:COM;NASDAQ:CRME), Vancouver, B.C. Aspen Pharmacare Holdings Ltd. (JSE:APN), Durban, South Africa Business: Cardiovascular Cardiome granted Aspen exclusive rights to commercialize Cardiomes IV …

    Published on 1/26/2015
  • Genmab, J&J deal

    Genmab A/S (CSE:GEN;OTCBB:GMXAY), Copenhagen, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Cancer Genmab received a $3 million milestone payment from Johnson & Johnsons Janssen Biotech Inc. unit …

    Published on 1/26/2015
  • Johns Hopkins University, Tokai deal

    Johns Hopkins University, Baltimore, Md. Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), Cambridge, Mass. Business: Diagnostic Johns Hopkins granted Tokai an exclusive, worldwide license to the universitys assay to determine …

    Published on 1/26/2015
  • Locate, Heraeus Medical deal

    Locate Therapeutics Ltd., Nottingham, U.K. Heraeus Medical GmbH, Wehrheim, Germany Business: Musculoskeletal Locate Therapeutics granted Heraeus an exclusive license to IP covering Locates TAOS thermo-responsive polymer…

    Published on 1/26/2015
  • Mars Symbioscience, Calithera Biosciences deal

    Mars Symbioscience, Germantown, Md. Calithera Biosciences Inc. (NASDAQ:CALA), South San Francisco, Calif. Business: Cancer Mars Symbioscience granted Calithera an exclusive, worldwide license to develop and …

    Published on 1/26/2015
  • Monash University, 60 Degrees Pharmaceuticals deal

    Monash University, Victoria, Australia 60 Degrees Pharmaceuticals LLC, Washington, D.C. Business: Infectious Monash University granted 60 Degrees 60P Australia Pty. Ltd. subsidiary exclusive rights to develop …

    Published on 1/26/2015
  • Novartis, Array BioPharma deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Business: Cancer Array will purchase from Novartis worldwide rights to develop and commercialize Phase III product …

    Published on 1/26/2015
  • PPD, Alexion deal

    PPD LLC, Wilmington, N.C. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Business: Pharmaceuticals PPDs X-Chem Inc. subsidiary will use its DNA-encoded small molecule library to discover drug candidates …

    Published on 1/26/2015
  • Sellas, Catalent Pharma deal

    Sellas Life Sciences Group, Zurich, Switzerland Catalent Pharma Solutions Inc., Somerset, N.J. Business: Neurology Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinsons disease (PD) and …

    Published on 1/26/2015
  • University of California, MiNA Therapeutics deal

    University of California, San Francisco, Calif. MiNA Therapeutics Ltd., London, U.K. Business: Other The University of California, San Francisco granted MiNA Therapeutics exclusive rights to IP developed at UCSF related…

    Published on 1/26/2015
  • Zymeworks, Celgene deal

    Zymeworks Inc., Vancouver, B.C. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Antibodies Zymeworks and Celgene partnered under a multiyear deal to develop and commercialize preclinical, bispecific antibodies …

    Published on 1/26/2015
  • AC Immune, J&J deal

    AC Immune S.A., Lausanne, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Neurology AC Immune and Johnson & Johnsons Janssen Pharmaceuticals Inc. unit partnered to develop and commercialize AC …

    Published on 1/19/2015
  • Agios, Celgene deal

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer Celgene exercised an option to license exclusive ex-U.S. rights to Agios AG-120, an inhibitor of …

    Published on 1/19/2015
  • Asklepion Pharmaceuticals, Retrophin deal

    Asklepion Pharmaceuticals LLC, Baltimore, Md. Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Business: Gastrointestinal Retrophin purchased cholic acid from Asklepion for $5 million up front. Asklepion is eligible for up …

    Published on 1/19/2015
  • Atreus Pharmaceuticals, Advanced Accelerator Applications deal

    Atreus Pharmaceuticals Corp., Ottawa, Ontario Advanced Accelerator Applications S.A., Saint Genis Pouilly, France Business: Diagnostic Advanced Accelerator Applications (AAA) acquired the remaining 49.9% of Atreus that …

    Published on 1/19/2015
  • Baylor Research Institute, Swedish Orphan Biovitrum deal

    Baylor Research Institute, Dallas, Texas Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Autoimmune Swedish Orphan received non-exclusive rights to Baylors patents covering the treatment of systemic …

    Published on 1/19/2015
  • Convergence Pharmaceuticals, Biogen Idec deal

    Convergence Pharmaceuticals Ltd., Cambridge, U.K. Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Business: Neurology Biogen is acquiring Convergence for $200 million up front and up to $475 million in milestone payments.…

    Published on 1/19/2015
  • Foundation Medicine, Roche deal

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic Roche partnered with Foundation Medicine to develop diagnostics and will acquire 52.4-56.3% of…

    Published on 1/19/2015
  • Human Longevity, Genentech deal

    Human Longevity Inc., San Diego, Calif. Genentech Inc., South San Francisco, Calif. Business: Genomics Roches Genentech Inc. unit partnered with Human Longevity to identify therapeutic targets and diagnostic biomarkers …

    Published on 1/19/2015
  • J&J, Depomed deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Depomed Inc. (NASDAQ:DEPO), Newark, Calif. Business: Neurology Depomed will purchase U.S. rights to the Nucynta tapentadol analgesic franchise from Johnson & Johnsons …

    Published on 1/19/2015
  • Meiji Seika Pharma, Fedora Pharmaceuticals, Roche deal

    Meiji Seika Pharma Co. Ltd., Tokyo, Japan Fedora Pharmaceuticals Inc., Edmonton, Alberta Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Infectious Meiji and Fedora granted Roche exclusive, ex-Japanese rights …

    Published on 1/19/2015
  • Moderna Therapeutics, Merck deal

    Moderna Therapeutics Inc., Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious The companies partnered to discover, develop and commercialize five mRNA-based treatments and …

    Published on 1/19/2015
  • NPS, Shire deal

    NPS Pharmaceuticals Inc. (NASDAQ:NPSP), Bedminster, N.J. Shire plc (LSE:SHP;NASDAQ:SHPG), Dublin, Ireland Business: Ophthalmic Shire will acquire rare disease company NPS in a deal worth $5.2 billion. Shire will pay $46…

    Published on 1/19/2015
  • OnCore Biopharma, Tekmira deal

    OnCore Biopharma Inc., Doylestown, Pa. Tekmira Pharmaceuticals Corp. (TSX:TKM;NASDAQ:TKMR), Burnaby, B.C. Business: Infectious OnCore will merge with a wholly owned subsidiary of Tekmira in a deal that the companies say…

    Published on 1/19/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993